Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 3
2019 pubmed

Humanin prevents undesired apoptosis of chondrocytes without interfering with the anti-inflammatory effect of dexamethasone in collagen-induced arthritis.

Celvin. Bettina B; Zaman. Farasat F; Aulin. Cecilia C; Sävendahl. Lars L

Key Findings

  • HNG prevented dexamethasone‑induced apoptosis in both joint and growth‑plate cartilage
  • HNG did not diminish the anti‑inflammatory effect of dexamethasone
  • Combined HNG and dexamethasone improved clinical and histology scores without extra side effects

Practical Outcomes

  • For biohackers or patients on chronic glucocorticoids, co‑administering a humanin analogue could theoretically safeguard cartilage and bone growth. The mouse dose was 100 µg/kg daily alongside 0.25 mg/kg dexamethasone, but human safety and efficacy are untested, so any use should await clinical trials.

Summary

In a mouse arthritis model, adding a synthetic humanin peptide (HNG) to dexamethasone stopped the drug from killing cartilage cells while still letting dexamethasone reduce joint inflammation. This means the peptide might protect bone growth when steroids are used long‑term, but the evidence is still only in animals.

Abstract

Prolonged use of glucocorticoids (GCs) for treatment of inflammatory and autoimmune conditions may have several negative side effects, such as impaired bone growth which has been linked to increased apoptosis in growth plate chondrocytes. It has recently been shown that humanin, a small mitochondrial derived peptide, rescues growth plate chondrocytes from GC-induced apoptosis. Our aim was to study if a synthetic analogue of humanin, [Gly14]-HNG (HNG), can be safely used to prevent GC-induced toxicity in growth plate chondrocytes without interfering with the desired anti-inflammatory effect in an in vivo model of arthritis. Arthritis was induced in DBA/1 mice by collagen type II in complete Freund's adjuvant and the animals were treated with Dexamethasone (Dexa) (0.25 mg/kg/day) with or without HNG (100 μg/kg/day) for 14 days. The animals were observed daily for the presence of arthritis including signs of erythema and swelling of the joints. The paws were scored based on the severity of the swelling. After termination, histological scoring was performed of all paws. Chondrocyte apoptosis and proliferation were analysed by TUNEL assay and PCNA staining, respectively. We found that HNG treatment in combination with Dexa protected from Dexa-induced chondrocyte apoptosis in both articular and growth plate cartilage. Furthermore, based on clinical and histology scoring analyses, HNG did not interfere with the desired anti-inflammatory effect of Dexa. Our results suggest that the combination of HNG and GCs may provide a new treatment strategy in conditions of chronic inflammation, which could potentially prevent bone growth impairment.

Study Information

Provider

pubmed

Year

2019

Date

2019-06-06T00:00:00.000Z